Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb;84(4):478–481. doi: 10.1054/bjoc.2000.1605

The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel

A Figer 1, L Irmin 1,3, R Geva 1, D Flex 1, J Sulkes 2, A Sulkes 1, E Friedman 3
PMCID: PMC2363777  PMID: 11207041

Abstract

Inherited predisposition occurs in 5–10% of all gastrointestinal (GI) cancer patients, but with the exception of colorectal cancer (CRC), the genes involved in conferring genetic susceptibility remain largely unknown. Indirect evidence indicates that germline mutations in BRCA2 might be associated with an increased risk for various GI malignancies. A single mutation (6174delT) occurs in the BRCA2 gene in high-risk breast ovarian cancer families of Jewish Ashkenazi origin, in about 1% of the general Ashkenazi population, and rarely in non-Ashkenazi Jews. In order to assess the contribution of this germline mutation to non-CRC GI cancer in Jewish Israeli patients, we tested 70 unselected, consecutive Jewish Ashkenazi patients with gastrointestinal malignancies for this mutation by PCR amplification and modified restriction enzyme digests. Patients' age range was 38–90 years (mean 65.8±11.8 years). The most common malignancies were gastric cancer (n = 35) and exocrine pancreatic cancer (n = 23). Overall, 6 mutation carriers were detected: 3/23 (13%) of the patients with pancreatic cancer, 2/35 (5.7%) of patients with gastric cancer and 1/4 (25%) of patients with bile duct cancer. The 8.6% mutation carrier rate among patients is a rate significantly higher than that of the general Ashkenazi population (1.16%P = 0.0002). We conclude that the rate of the predominant Jewish BRCA2 mutation in patients with gastric and pancreatic cancer significantly differ from that of the general population of the same ethnic origin. Thus, BRCA2 mutations probably contribute to gastrointestinal tumorigenesis other then colon cancer, and the surveillance scheme for mutation carriers should incorporate this information. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: BRCA 2, Jewish founder mutation, non-colon cancer, inherited predisposition to cancer

Full Text

The Full Text of this article is available as a PDF (53.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abeliovich D., Kaduri L., Lerer I., Weinberg N., Amir G., Sagi M., Zlotogora J., Heching N., Peretz T. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997 Mar;60(3):505–514. [PMC free article] [PubMed] [Google Scholar]
  2. Bar-Sade R. B., Kruglikova A., Modan B., Gak E., Hirsh-Yechezkel G., Theodor L., Novikov I., Gershoni-Baruch R., Risel S., Papa M. Z. The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum Mol Genet. 1998 May;7(5):801–805. doi: 10.1093/hmg/7.5.801. [DOI] [PubMed] [Google Scholar]
  3. Easton D. F., Matthews F. E., Ford D., Swerdlow A. J., Peto J. Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer. 1996 Jan 26;65(3):284–294. doi: 10.1002/(SICI)1097-0215(19960126)65:3<284::AID-IJC2>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  4. Falk R. T., Pickle L. W., Fontham E. T., Correa P., Fraumeni J. F., Jr Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. Am J Epidemiol. 1988 Aug;128(2):324–336. doi: 10.1093/oxfordjournals.aje.a114972. [DOI] [PubMed] [Google Scholar]
  5. Fernandez E., La Vecchia C., D'Avanzo B., Negri E., Franceschi S. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 1994 Apr-May;3(3):209–212. [PubMed] [Google Scholar]
  6. Ghadirian P., Boyle P., Simard A., Baillargeon J., Maisonneuve P., Perret C. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol. 1991 Nov-Dec;10(3-4):183–196. doi: 10.1007/BF02924156. [DOI] [PubMed] [Google Scholar]
  7. Goggins M., Schutte M., Lu J., Moskaluk C. A., Weinstein C. L., Petersen G. M., Yeo C. J., Jackson C. E., Lynch H. T., Hruban R. H. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996 Dec 1;56(23):5360–5364. [PubMed] [Google Scholar]
  8. Hartge P., Struewing J. P., Wacholder S., Brody L. C., Tucker M. A. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet. 1999 Apr;64(4):963–970. doi: 10.1086/302320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hu N., Roth M. J., Emmert-Buck M. R., Tang Z. Z., Polymeropolous M., Wang Q. H., Goldstein A. M., Han X. Y., Dawsey S. M., Ding T. Allelic loss in esophageal squamous cell carcinoma patients with and without family history of upper gastrointestinal tract cancer. Clin Cancer Res. 1999 Nov;5(11):3476–3482. [PubMed] [Google Scholar]
  10. Katagiri T., Nakamura Y., Miki Y. Mutations in the BRCA2 gene in hepatocellular carcinomas. Cancer Res. 1996 Oct 15;56(20):4575–4577. [PubMed] [Google Scholar]
  11. Lal G., Liu G., Schmocker B., Kaurah P., Ozcelik H., Narod S. A., Redston M., Gallinger S. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res. 2000 Jan 15;60(2):409–416. [PubMed] [Google Scholar]
  12. Lissowska J., Groves F. D., Sobin L. H., Fraumeni J. F., Jr, Nasierowska-Guttmejer A., Radziszewski J., Regula J., Hsing A. W., Zatonski W., Blot W. J. Family history and risk of stomach cancer in Warsaw, Poland. Eur J Cancer Prev. 1999 Jul;8(3):223–227. doi: 10.1097/00008469-199906000-00010. [DOI] [PubMed] [Google Scholar]
  13. Lynch H. T., Fusaro L., Lynch J. F. Familial pancreatic cancer: a family study. Pancreas. 1992;7(5):511–515. doi: 10.1097/00006676-199209000-00001. [DOI] [PubMed] [Google Scholar]
  14. Oddoux C., Struewing J. P., Clayton C. M., Neuhausen S., Brody L. C., Kaback M., Haas B., Norton L., Borgen P., Jhanwar S. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet. 1996 Oct;14(2):188–190. doi: 10.1038/ng1096-188. [DOI] [PubMed] [Google Scholar]
  15. Ozçelik H., Schmocker B., Di Nicola N., Shi X. H., Langer B., Moore M., Taylor B. R., Narod S. A., Darlington G., Andrulis I. L. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet. 1997 May;16(1):17–18. doi: 10.1038/ng0597-17. [DOI] [PubMed] [Google Scholar]
  16. Palli D., Galli M., Caporaso N. E., Cipriani F., Decarli A., Saieva C., Fraumeni J. F., Jr, Buiatti E. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):15–18. [PubMed] [Google Scholar]
  17. Phelan C. M., Lancaster J. M., Tonin P., Gumbs C., Cochran C., Carter R., Ghadirian P., Perret C., Moslehi R., Dion F. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet. 1996 May;13(1):120–122. doi: 10.1038/ng0596-120. [DOI] [PubMed] [Google Scholar]
  18. Roa B. B., Boyd A. A., Volcik K., Richards C. S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996 Oct;14(2):185–187. doi: 10.1038/ng1096-185. [DOI] [PubMed] [Google Scholar]
  19. Rohlfs E. M., Learning W. G., Friedman K. J., Couch F. J., Weber B. L., Silverman L. M. Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem. 1997 Jan;43(1):24–29. [PubMed] [Google Scholar]
  20. Struewing J. P., Coriaty Z. M., Ron E., Livoff A., Konichezky M., Cohen P., Resnick M. B., Lifzchiz-Mercerl B., Lew S., Iscovich J. Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet. 1999 Dec;65(6):1800–1802. doi: 10.1086/302678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Struewing J. P., Hartge P., Wacholder S., Baker S. M., Berlin M., McAdams M., Timmerman M. M., Brody L. C., Tucker M. A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997 May 15;336(20):1401–1408. doi: 10.1056/NEJM199705153362001. [DOI] [PubMed] [Google Scholar]
  22. Thorlacius S., Sigurdsson S., Bjarnadottir H., Olafsdottir G., Jonasson J. G., Tryggvadottir L., Tulinius H., Eyfjörd J. E. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997 May;60(5):1079–1084. [PMC free article] [PubMed] [Google Scholar]
  23. Tulinius H., Egilsson V., Olafsdóttir G. H., Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ. 1992 Oct 10;305(6858):855–857. doi: 10.1136/bmj.305.6858.855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Zanghieri G., Di Gregorio C., Sacchetti C., Fante R., Sassatelli R., Cannizzo G., Carriero A., Ponz de Leon M. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer. 1990 Nov 1;66(9):2047–2051. doi: 10.1002/1097-0142(19901101)66:9<2047::aid-cncr2820660934>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES